Antibodies to the phospholipase A2 receptor 1 (PLA2R1) have been reported in 70% of cases of idiopathic membranous nephropathy (IMN). The genetic susceptibility of IMN has been accounted for by HLA DQA1 and PLA2R1 genes. Here we retrospectively quantified PLA2R antibodies by ELISA, and genotyped DQ alleles and PLA2R1 singlenucleotide polymorphisms for association with clinical criteria for disease activity at the time of first sample and with outcome over a median total follow-up of 90 months. In 90 prevalent patients with biopsy-proven IMN, anti-PLA2R antibodies were present in 75% of patients with IMN with active disease and were significantly higher than in patients in partial or complete remission at the time of antibody measurement. There was a differential IgG subclass response (4424341) at an early stage, i.e., within 6 months of biopsy. Levels of PLA2R antibodies were significantly linked to DQA1*05:01 and DQB1*02:01. Survival analysis of patients with IMN showed that PLA2R antibodies are significantly linked with outcome. Thus, high levels of PLA2R antibodies are linked with active disease and a higher risk of declining renal function during follow-up. Future therapeutic trials in IMN should monitor anti-PLA2R, as patients with a high antibody burden may benefit from earlier therapeutic intervention.
Idiopathic membranous nephropathy (IMN) has long been suspected of having an immune etiology. Renal biopsy findings on light microscopy, 1 immunofluoresence staining for IgG and C3 deposition along the glomerular capillary wall, 2 electron-dense deposits of immune reactants in the sub-epithelial glomerular basement membrane, 3 the link with HLA DR 4 and DQ, 5 and the association with complement activation products and disease activity 6, 7 all imply that immune dysregulation underlies the clinical disease. However, only in the past decade has definitive proof become available that autoimmunity could be central to the immune diathesis producing a membranous nephropathy (MN) pattern of renal pathology. In 2002, neutral endopeptidase (CD10) 8 was established as the first recognized autoantigen occurring in and causative of MN (in infants after allogeneic immunization during pregnancy).
Confirmation that IMN has an underlying autoimmune pathogenesis came from the discovery of antibodies to phospholipase A2 receptor 1 (PLA2R1) in 70% of cases. 9 The recent genome-wide association study of 556 IMN cases shows that genetic susceptibility is only accounted for by possession of disease alleles of HLA DQA1 and PLA2R1. 10 Clinical studies have shown that the level of a-PLA2R is substantially reduced by rituximab treatment, which, in the short term, is associated with clinical benefit. 11 Further, there is some evidence that the IgG4 subclass may be the dominant component of a-PLA2R. 9, 12 More evidence is required to identify the relationship between a-PLA2R levels and clinical parameters of disease activity and outcome to inform the clinician about the implications of a-PLA2R measurement in each major patient category: those with active disease, in partial remission, and in complete remission. Therefore, by deliberately choosing a prevalent patient population, which all clinicians manage (i.e, not only new incident patients or active patients entering a therapeutic trial but those selected over time and by treatment or spontaneous remission into categories of partial remission and complete remission), we sought to establish the association of a-PLA2R as a marker of the further outcome of these selected groups.
We investigated, retrospectively, a-PLA2R levels in 90 patients with IMN, where prospective collection of serum and DNA had been biobanked together with clinical data (Table 1 ) and with total follow-up over 90 months. We developed the first quantitative ELISA for robust reporting of abnormal a-PLA2R levels against a normal range, and we sought to establish which of the known 35 alleles of DQA1 (as conventionally detected for organ matching) are linked with the development of a-PLA2R. We have quantified the a-PLA2R subclass pattern in early presentation of disease and assessed the role of a-PLA2R as an aid in the management of prevalent patients at different stages of disease. The primary hypothesis that we are testing in this study of prevalent patients with IMN is that a quantitative assay of a-PLA2R levels shows association with current disease activity. The secondary hypothesis is that levels of a-PLA2R in prevalent patients are predictive of clinical outcome.
RESULTS

High levels of a-PLA2R are linked with active disease
A-PLA2R assay was performed on the first available sample for each patient, taken at a median interval of 29 months (interquartile range (IQR) 9-88 months) from the onset of disease. At this time of first sampling (Table 2) , 30/40 (75%) patients with active disease, 10/27 (37%) of those in partial remission, and 2/23 (10%) in complete remission were a-PLA2R positive. All three groups had a similar follow-up period from the time of antibody assay (median ¼ 33, IQR 9-59 months; P ¼ 0.15). Median a-PLA2R levels were significantly higher in the active disease group, 170.8 m/ml (39-502), compared with those in PR, 28.2 m/ml (13-49), or CR, 23.7 m/ml (17-30) (Po0.001), respectively ( Figure 1a ). There was no significant difference in a-PLA2R levels between PR and CR groups (P ¼ 0.27). A-PLA2R levels in the total group correlated significantly with the degree of proteinuria (r ¼ 0.51 and Po0.001, Figure 1b ).
a-PLA2R IgG subclass response
There was a high correlation of IgG4 a-PLA2R with total a-PLA2R levels in the whole group (r ¼ 0.789, Po0.001, Figure 1c ). To establish the natural pattern of IgG subclass response to PLA2R early in presentation, a subset of patients (n ¼ 20) whose initial biopsy and serum sample were taken within 6 months, without intervening immunosuppression, were further studied. In all, 15/20 patients were positive for total a-PLA2R, and sera were measured for specific subclass a-PLA2R. The median (IQR) for the %IgG1, %IgG2, %IgG3, and %IgG4 are significantly different at 8.7% (3.5-20.8), 31.6% (14.6-37.7), 5.9% (0-15.2), and 50.0% (10.8-61.6), respectively, (P ¼ 0.001) (Figure 1d ).
Association of a-PLA2R and disease genes DQA1 and PLA2R DQ typing for known alleles of HLA DQA1 and DQB1 for groups with allele frequency X5/group is shown in association with a-PLA2R levels (Figure 1e and f). The presence of one or two alleles of HLA DQA1*05:01 was significantly associated with higher antibody levels than those without the *05:01 allele (P ¼ 0.001). DQB1 *02:01 was associated with higher a-PLA2R levels (P ¼ 0.049). SNPs in exon 5 (rs3749117) and intron 1 (rs4664308) of the PLA2R1 gene were assessed for association with a-PLA2R (Figure 2) . A-PLA2R levels were not significantly higher with exon 5 SNP AA genotype compared with the AG/GG type (P ¼ 0.08). There was no demonstrable effect of intron 1 SNP on a-PLA2R levels ( Figure 2 ) (See Supplementary data online for all DQA1 associations).
High levels of a-PLA2R are associated with disease progression
For all patients (82/90) who had not reached doubling of serum creatinine by the time of blood sampling, a survival analysis over 5 years for doubling of serum creatinine in relation to tertiles of a-PLA2R at sampling date showed a striking increase in the risk of progression in patients with high a-PLA2R (Cox regression adjusted for treatment, Po0.001) ( Figure 3 ). However, there were no significant associations of a-PLA2R levels with gender and ethnicity (see Supplementary data online). Two patients with active disease, who experienced spontaneous remission, are shown with prospective measurement of a-PLA2R annually for several years ( Figure 4a and b) , illustrating a change of a-PLA2R with levels of proteinuria.
DISCUSSION
The discovery of a-PLA2R 9 in patients with IMN presents a new opportunity to improve the understanding and clinical management of MN. To date, studies on a-PLA2R in IMN have used either western blotting 9,12,13 or immunofluorescence techniques [14] [15] [16] that are semiquantitative, timeconsuming when applied to large numbers of samples, subject to large variation between assay batches, and often run in a mode requiring subjective observer assessment. We describe here in detail the first ELISA using extracellular recombinant PLA2R1 (rPLA2R1) to quantify a-PLA2R in a single -center-prevalent group of biopsy-proven IMN patients. This assay, which defines the normal range and sets an objective threshold for discrimination between positive and negative results in clinical studies, has allowed us to investigate the effect of genetics (DQ, PLA2R) on antibody levels and establish associations with disease activity and clinical outcomes using stored samples and clinical data from the biobank. This study shows that 75% of patients with active disease are a-PLA2R positive, whereas only 37% of patients in partial remission and 10% of patients in complete remission are positive. This corresponds to a positivity rate of 46% for our total prevalent population, unselected for disease activity. Setting the positivity threshold at 4mean þ 3s.d. of the normal range identifies 1/73 controls as positive. The level of a-PLA2R is significantly higher in patients with active disease compared with either PR or CR patients. A-PLA2R levels in PR (28.2 m/ml; 13-49) and CR (23.7; 17-30) are not significantly different, with the majority of patients within the normal range (PR 63%; CR 90%) despite displaying a large difference, by definition, in proteinuria. Other factors, such as resolution of glomerular scarring/healing, may influence proteinuria during the remission phase after disappearance of serum a-PLA2R. The original study by Beck et al. 9 reported a-PLA2R positivity by western blotting in 26/37 (70%) prevalent IMN patients, of whom only 17/37 (46%) had active disease. Another study from Boston 12 in a European cohort of active IMN patients with nephroticrange proteinuria reported 14/18 (78%) positivity by western blotting, where the a-PLA2R is substantially reduced in remission and recurs in relapse. The same laboratory 13 reported, in a Chinese population, 82% (49/60 ) positivity by western blotting in an active disease group, all with nephrotic-range proteinuria and serum taken on the day of biopsy, with 19% (4/21) positivity in a separate IMN group in remission. Our results using ELISA assay independently confirm that the level of a-PLA2R and the percentage positivity is related to disease activity in IMN, with only the active disease group displaying the highest positivity (75%) and highest a-PLA2R level. Demonstration of a significant correlation between a-PLA2R levels and proteinuria at the time of sampling across the whole group reinforces the likelihood that a-PLA2R may have a pathogenic role.
To describe the natural pattern of the IgG subclass response to PLA2R, we analyzed a subset of patients (n ¼ 15) whose serum and biopsy samples were taken within 6 months and who were untreated by immunosuppressive agents before sampling. IgG4 and IgG2 subclasses, typically thought to be inefficient at complement fixation, were clearly dominant, constituting 50 and 37%, respectively, of the total subclass response. The IgG4/IgG1 ratio in a-PLA2R in this group is 5.7. We previously described 3.5-fold and 5.7-fold enrichment of total IgG4 subclass over IgG1 subclass in glomerular eluates from membranous kidneys in comparison with normal kidneys and anti-GBM kidneys, respectively, ( 17 ). This specific a-PLA2R IgG4 enrichment quantified by ELISA is also consistent with the IgG subclass pattern found by western blotting 9 and immunostaining of biopsies. 18, 19 There was a clear correlation between the IgG4 subclass and total a-PLA2R response, but the relative pathogenicity of individual subclass a-PLA2R-A awaits future testing.
The dominant genetic effect of DQA1, as seen in the genome-wide association study study using SNP association to determine susceptibility to IMN, 10 has not yet been related to a-PLA2R levels and interpreted in the context of known DQ alleles as typed for organ matching. This study confirms an association of a gene dose effect seen with DQA1 *05:01 and high a-PLA2R levels, which is the first defined link of a DQ allele and the autoantibody. Sequence-based analysis of the DQA1 gene is still identifying novel alleles, 20 and through such methods a novel pathogenic allele may yet be confirmed. Analysis of DQB1 alleles shows that DQB1 *02:01 is linked with a-PLA2R, strongly suggesting that DQ2.3 (DQA1 *05:01; DQB1 *02:01) mediates the genetic risk for autoantibody production. DQ2.3 is already established as a strong risk factor for other autoimmune diseases, notably Type I diabetes 21 and celiac disease. 22 In celiac disease, susceptibility is currently explained by preferential binding of gliadin peptide to the DQ receptor. 23 Knowledge of the peptide sequence requirements for optimum interaction with DQ2.3 gained from study of these autoimmune diseases 24 enables prediction of sequences within PLA2R that could act as T-cell epitopes in initiation of the autoimmune mechanism in IMN. Recent studies of peptides binding to six major DQ molecules identify a significant overlap in peptide-binding repertoires. 25 Therefore, putative peptides will require in vitro T-cell-binding studies to confirm those that are predominant in providing T-cell help for a-PLA2R production.
With regard to the two SNPs in PLA2R (rs3749117; exon 5 V292M and rs4664308 intron 1) identified as conferring a high risk for IMN in genome-wide association study, 10 we found a marginal association (P ¼ 0.08; adjusted for treatment) with exon 5 V292M and a-PLA2R levels in this study of 90 patients. Further analysis of PLA2R SNP haplotypes in a much larger group of a-PLA2R-positive, immunosuppression-naïve patients may yet identify an association.
Observation of a very significant association across the whole group of prevalent cases linking poor clinical outcome with a-PLA2R levels (P40.001) may bear an important message for clinical management of IMN (Figure 3) . The clinical course of a prevalent MN population over a period of 5 years or longer is subject to many influences including prior and further immunosuppression, as well as factors inherent in the disease mechanism. There is a risk of future relapse in patients in remission, achieved either spontaneously or induced with therapy. Similarly, patients with active disease may enjoy a spontaneous or treatment-induced remission over a period of 5 years or longer. Our observation suggests a contributory association between high a-PLA2R and risk of renal decline, but does not prove cause and effect. As we show in two patients of active disease who experience spontaneous remission, longitudinal levels of a-PLA2R and proteinuria appear to be linked synchronously in case 1 (Figure 4a ), but in case 2 (Figure 4b ) proteinuria is resolving in the face of a high a-PLA2R level, which subsequently resolves within a year. These two cases illustrate a high degree of variability in the linkage between serum a-PLA2R level and podocyte dysfunction as measured by proteinuria, which requires both a prospective study of a large number of patients and additional biomarkers of the pathological damage, e.g., C5b-9, in order to fully explain the mechanism. 7 We have presented evidence to support our primary hypothesis that, in a large prevalent group of IMN patients, a-PLA2R antibodies measured by ELISA are associated with active disease and proteinuria and poor clinical outcome. Clearly, this cross-sectional analysis of a-PLA2R in a prevalent MN population has some limitations, as we only measure a-PLA2R on one occasion and report outcomes over the longer term. Patients in a prevalent study are at varying stages in their immunosuppression treatment, some treated and others not treated, and we have taken this into account in the analysis. These issues can be addressed in prospective clinical trials of new incident patients, which are currently being established but will take up to 5 years to report outcomes. Our data support the use of a-PLA2R ELISA in such studies.
In the setting of the patient whose disease remains clinically active, one begins to question the value of maintaining a conservative approach of waiting for months before therapeutic intervention in the face of a high level of a-PLA2R. The passive transfer of a-PLA2R in animal models is the only way to prove Koch's postulate for cause and effect for pathogenicity. 26 Until that is proven, we suggest that the clinical evidence that a-PLA2R may cause damage to the kidney in IMN is powerful.
MATERIALS AND METHODS Patients and clinical phenotype
A total of 90 prevalent patients with biopsy-proven IMN at the Manchester University Hospitals were recruited into the study carried out under ethics reference 06/Q1401/5 and 10/H1008/10. Demographic details of the 90 patients are presented in Table 1 . Patients were included in this study on the basis that the following were available: (a) serum sample for a-PLA2R test, (b) DNA for HLA DQ typing and SNP typing of PLA2R, and (c) serial clinical data including follow-up for at least 2 years from onset. The use of immunosuppressive agents was recorded. The following criteria were used to classify the activity of disease, using established criteria. 27 Active disease. Active disease was defined as a 24-h proteinuria 43.5 g or persistence of X50% baseline proteinuria or 425% increase in serum creatinine.
Partial remission. Partial remission was defined as a 24-h proteinuria of 0.3-3.5 g and reduction of proteinuria to at least 50% of baseline, with stable renal function (p25% increase in serum creatinine).
Complete remission. Complete remission was defined as a 24-h proteinuria o0.3 g, with stable renal function (p25% increase in serum creatinine). Proteinuria was assessed on 24-h urine collections or calculated as equivalent values from urine proteincreatinine ratios.
It is important to note that there were no differences in proteinuria and creatinine in the disease groups at disease onset ( Table 2 ). In addition, there were no differences in immunosuppression before sample assay. In all, 10/23 (43%) CR patients, 12/27 (44%) PR patients, and 12/40 active disease group patients (30%) received immunosuppression before antibody assay ( Table 2) . Of the 45 patients from all groups who received IS, 34 patients received treatment before sampling and 11 received treatment after sampling. Spontaneous remission was observed in 39 patients who initially presented with a median proteinuria of 6.7 g/24 h (IQR 4.6-9.3). Partial and complete remission groups were of significantly longer vintage (median 51 and 55 months, respectively) at the time of a-PLA2R assay than the active disease group (median 8 months).
Cloning of PLA2R
The extracellular DNA sequence of PLA2R ((HGNC:9042) Genbank acc no U17033) was cloned in two parts (A covering nts 1-1359 and B, nts 1360-4205) in pUC57 transfer vector. After digestion with XhoI/NotI enzymes, sequences were verified and clones A and B were ligated and recloned into pUC57. After digestion with NheI/NotI, the full-length sequence was inserted into pCep-Pu for protein expression with the addition of N-terminal BM-40 signal peptide sequence and C-terminal (His) 10 tag (Figure 5a and b) (see Supplementary data online for more detail).
Expression of PLA2R
HEK 293 EBNA1 cells were transfected with pCep-Pu:PLA2R and grown in DMEM (serum free) for up to a week (Figure 5c ). The medium was concentrated and applied to a nickel-chelate column for purification by affinity chromatography. rPLA2R was analyzed by SDS-PAGE gels and western blotting with anti-His tag antibodies (Generon, Maidenhead, UK) and anti-PLA2R (Sigma Aldrich, Poole,UK) (Figure 5d ). Purified rPLA2R (Figure 5e ) was subjected to trypsin digestion and mass spectrometry to validate the identity of the protein sequence (Data not shown).
PLA2R ELISA for total IgG
The purified rPLA2R protein was used to coat ELISA plates at a concentration of 0.125 mg/ml in sodium bicarbonate buffer of pH 9.6 for 18 h. Plates were blocked for 1 h with SuperBlock (Thermo Fisher Scientific, Cramlington, UK) and kept at 4 1C until use (within 3 days). Patient serum diluted 1:100 in superblock containing 0.1% Tween 20 was added in duplicate 100-ml aliquots to the ELISA plate, which also contained a standard dilution series of STD2 and QC1 in duplicate wells (a between-plate quality control sample). After 2 h of incubation at room temperature on a plate shaker, the plates were washed thoroughly (8 times) with PBS plus 0.1% Tween 20. Anti-human IgG-HRP conjugate (Jackson ImmunoResearch, Newmarket, UK) diluted 1:25,000 in Superblock was added (100 ml per well) and incubated for 2 h as described earlier. After washing as described earlier, enzyme substrate TMB (Sigma Aldrich) was added, developed for 10 min, and the reaction was stopped with 0.5 mol/l H 2 SO4. The plates were read at 450 nm, standard curves were plotted using the Softmax software Molecular Devices (Sunnyvale, CA), and values were assigned to samples.
Standard STD2 was allocated a value of 99,000 m/ml and was a pool of high-titer samples (n ¼ 10) that had been microfuged and filtered through a 0.22-mm membrane, aliquoted, and stored at À 80 1C. For each ELISA plate, a dilution series covering the range of 3000-12.3 m/ml was applied to the plate.
Quality control
The assay was monitored for between-batch variation by incorporating an aliquot of the QC sample in duplicate on each plate. The QC sample was a pool of IMN sera (n ¼ 10) with borderline positivity (53 m/ml) that had been processed and stored in the same manner as STD2. Results from 22 different plate batches show a coefficient of variation of 17.8%. Samples applied to the same plate report o8% variation (Reduction of the coated antigen using 100 mmol/l DTT ablated antibody binding).
Normal range of a-PLA2R values; definition of high a-PLA2R; positivity in disease control A total of 73 serum samples from healthy individuals (M:F ¼ 20:53, white 59, Asian 9, Afro Caribbean 5; mean age 41 ± 10 years) were used to define the normal range. By using mean þ 3 s.d. of the normal range, we describe samples above 40 m/ml as 'positive' , although we report even lower values within the normal range. The medium was concentrated and the buffer was exchanged (50 mmol/l NaP, 0.3 mmol/l NaCl pH8.2) using Vivaspin20 columns (Sartorius). Triton X-100 was added (0.2% final concentration) before loading the medium on prewashed nickel NTA resin (Generon) for binding to occur, while rocking it for 4 h at 4 1C. The washing steps (15 min at 4 1C) were performed with increasing concentrations of imidazole (from 10 to 50 mmol/l). The bound protein was eluted in 250 mmol/l imidazole in the buffer. Eluted fractions were resolved on an 8% SDS-PAGE gel and stained with Coomassie blue. Finally, peak fractions were pooled and buffer was exchanged into PBS/20% glycerol and snap-frozen in small aliquots.
Specificity of a-PLA2R for IMN cases was confirmed by testing disease controls using 79 IgA Nephropathy cases and 3 anti-GBM cases, none of whom were positive. Of 19 biopsy-proven SLE nephritis cases showing MN Class V pathology, only one case (5%) was positive. On the basis of the unimodal distribution of a-PLA2R results in 90 patients (see Supplementary data online), we classified patients as having low, medium, and high titers based upon tertiles (low titer o24 m/ml, medium titer 24-88 m/ml, including some values within the normal range, and high titer 488 m/ml). This is the first ELISA described for a-PLA2R; it has been fully validated in a large European cohort of biopsy-proven idiopathic cases 14 in comparison with a commercially available immunofluorescence assay. 15 We show comparative data on 13 samples from patients with active disease analyzed by western blotting (serum dilution 1/10) with ELISA values (serum dilution 1/100) chosen to cover the range from 17 to 30,000 m/ml (Figure 6 ). For western blotting, the designation of positive/negative occurs in the range 25-71 m/ml as measured by ELISA.
PLA2R ELISA for IgG subclasses
The assay for IgG subclass a-PLA2Rab was similar to that described above, with each sample (dilution 1:100) applied to a set of four plates (See Supplementary file online).
PLA2R SNPs
TAQman PCR kits (Applied Biosystems, Paisley, UK) for two common SNPs-one in exon 5 (rs3749117) at position 292 A to G (methionine to valine substitution) and one in intron 1 (rs4664308)-were used to type the PLA2R variant in all patients.
DQ allele typing
High-resolution HLA DQA1 and DQB1 typing was performed using LABType SSO (One Lambda, Gateshead, UK), and typing of PLA2R variants was performed for the two SNPs showing the highest association with IMN (and in linkage disequilibrium, r 2 ¼ 0.7) 10 -one in exon 5 (rs3749117) at position A292G (methionine to valine substitution) and one in intron 1 (rs4664308).
Western blotting of a-PLA2R antibodies rPLA2R (300 ng/track) was run on a 10% SDS-PAGE gel under nonreducing conditions, and the gel was electroblotted onto immobilon membrane using semi-dry conditions. After blocking, each track was cut out and placed in a multiwell cassette for incubation with test sera at 1:10 dilution in Superblock containing 0.1% Tween 20 (See Supplementary file online).
Analysis
Clinical analyses were related to the date of blood sampling for a-PLA2R as the reference point. Statistical analysis was performed in R(v2.13). 28 For descriptive data, results were described with mean ( ± s.d.) and median (IQR) as appropriate. Mann-Whitney, Kruskal-Wallis, and Fisher's exact test were used for comparison between groups. Correlation was assessed with Spearman's coefficient, and outcome data were analyzed with Cox regression analysis. Where appropriate, adjustment for immunosuppressive treatment received as a time-dependent covariate was undertaken using a counting process formulation 29 and estimating the separate hazards for the periods before and after treatment and presented as a Kaplan-Meier graph. Associations of a-PLA2R with genotype were assessed using linear models for log-transformed levels against a number of alleles, adjusting for immunosuppression treatment before sampling. Doubling of serum creatinine was used as the primary end point. P-values o0.05 were considered significant.
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